anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Hematoma expansion (H-Ex) in small-/medium-sized acute epidural hematoma (AEDH) cases upon emergency admission is critical. Predicting H-Ex can lead to early surgical interventions, improving outcomes, and eliminating the need to check for expansion via computed tomography (CT). This study aimed to identify the most reliable predictors of AEDH expansion.
METHODS: We retrospectively collected data from patients with pure AEDH not requiring surgical treatment upon emergency admission from 2012 to 2022. We assessed clinical and laboratory data, time from injury to the first CT, and time to follow-up CT. Factors predictive of H-Ex on the second follow-up CT, including the leakage sign (LS), were analyzed.
RESULTS: A total of 23 patients with pure AEDH without surgery at admission were included, and LS was positive in 18. Thirteen patients showed H-Ex. The H-Ex group showed a significantly higher rate of positive LS and a lower mean platelet count than the group without H-Ex. LS's predictive value for AEDH expansion showed 100% sensitivity and 50% specificity. All patients with negative LS and normal platelet counts showed no H-Ex. Analyzing the time from injury to the first CT suggested that LS (+) within 120 minutes strongly predicted H-Ex. Reconstructed three-dimensional images of the leakage point on the skull revealed multiple mottled bleeding points on the dural surface.
CONCLUSIONS: LS can predict H-Ex in patients with pure AEDH for whom emergency surgery is unnecessary at admission. The time from injury and platelet counts must also be considered.
PURPOSE:To obtain a new compound useful as a preventing and a therapeutic agents for hypoxemia due to diseases in respiratory organs. CONSTITUTION:This compound is expressed by formula I [R<1> is H, alkyl, alkenyl or aralkyl ; R'' is alkyl, alkenyl or aralkyl; Y is cyclic amino (G<1> and G<2> are each 1-6C alkyl) such as formula II bound through N to the pyrimidine ring], e.g. 2-allylamino-4-(2,6-dimethylpiperidino)-7-methyl-7H-pyrrlo[2,3- d]pyrimidine. The compound expressed by formula I is obtained by reacting a compound expressed by formula III (X is halogen) with an amine expressed by the formula Y-H under alkaline conditions. The compound expressed by formula I is capable of enhancing the respiratory function in the lungs. Some thereof are capable of raising only the partial pressure of oxygen mainly in arterial blood and some have action on reduction in the partial pressure of gaseous carbon dioxide in the arterial blood together with a rise in the partial pressure of oxygen in the arterial blood.
A method for automatically classifying, by a computer processor, a clinical description of a patient using natural language processing is provided. The clinical description relates to the use of ventricular assist devices to treat patients. The method includes receiving at least one clinical description including text. The method then further includes determining a location of the target word within the text. Further, the method includes determining the presence of at least one negative word in an active region, the active region including a predetermined number of words in the text occurring immediately before and after the target word, including the target word. The method then includes determining the presence of at least one body part word within the active area. Finally, the method includes determining that if the active region contains a negative word or a body part word, the clinical description will be ignored.
Patients at high risk for venous thromboembolism (criteria: age\>=40, pelvic fracture, lower extremity fracture, shock on presentation, spinal cord injury, head injury with AIS \>=3) who also have a contraindication to anticoagulant(enoxaparin)administration such as renal failure with creatine clearance \<30 mL/min, head injury with head AIS \>=3), uncontrolled hemorrhage, uncorrected coagulopathy, persistent thrombocytopenia. These patients will receive mechanical compression.
PURPOSE: Provided is a method of preparing drink containing chlorophyll. Chlorophyll is extracted in a high yield and is not destroyed in the extraction process. The chlorophyll drink can be enjoyed anywhere and anytime. CONSTITUTION: The method comprises: grinding step of the plants containing chlorophyll after they are dried in the shade; and extraction step of chlorophyll wherein the above ground plants and the extracting solvent in a ratio of 50kg:100L are put into the extraction vessel keeping the temperature at 20-30deg.C stirring for 2-3 hours, precipitating for 24 hours to obtain a good quality extracted liquid, and maturing for 24 hours. The solvent being again added to the extracted solid in a ratio of 100 liters to 50kg and extracted for 2-3 hours with stirring; cold maturing step at 5-7deg.C for 24 hours; concentrating step wherein 48 liters of the above cold matured solution is introduced into a concentrating vessel to reduce to 12 liter solution by heating at 30-40deg.C, adding to it another 24 liter of the solution and concentrating for 4 hours. After repeating 10 times of concentrating step and obtaining 24 liters of the water soluble concentrated solution; water curing step of the above concentrate by adding the concentrate and cold water of 5-7deg.C and pH 7.2-7.5 in a ratio of 1.5 liters to 15 liters to the decomposition vessel of chlorophyll and by diluting; and packaging step of the drink after the above diluted solution is matured for 28 hours at 5-7deg.C and filtered.
A method of using 1,2,4-benzotriazine oxides, some of which are novel compounds, as radiosensitizers and selective cytotoxic agents is disclosed. These compounds are shown to specifically radiosensitize hypoxic tumor cells. Some are additionally disclosed to be useful as specific cytotoxic agents for these cells. They also show an unexpected ability to radiosensitize aerobic cells following or preceding a hypoxic incubation of the cells with the drug. This provides a basis for selective radiosensitization of tumors compared to normal cells.      Novel compounds of a novel method for preparing the 1,2,4-benzotriazine oxides is also disclosed. Novel compounds of the formula   wherein X is OH, alkoxy (1-4C), NHR or NRR where each R is independently an alkyl of 1-4 carbon atoms, or aryl of 1-4 carbon atoms, or where the two R groups are alkyls linked together to form a pyrrolidino or piperidino ring or linked through an oxygen to form a morpholino ring, and the R groups may be further substituted with OH, NH2, alkyl (1-4C) secondary amino, dialkyl (1-4C) tertiary amino, pyrrolidino, piperidino, alkoxy (1-4C), or halogen substitutents; n is 1; and Y1 is H and Y2 is nitro; or a pharmacologically acceptable salt thereof are also disclosed. A novel method for preparing the 1,2,4-benzotriazine oxides is also disclosed.
CURRARINO syndrome (CS) (OMIM 176450) is a rare congenital disease described in 1981, as the association of, at least, three main clinical features: typical sacral malformation (sickled-shape sacrum or total sacral agenesis below S2), hindgut anomalies and pre-sacral tumor. To date, neurological defects, as tethered cord and/or lipoma of the filum or the conus, are up lighted to be as a fourth major clinical sign.In half of cases, CS is ascribed to heterozygous mutations of the HLXB9 gene (or MNX1 gene, OMIM 142994) located at 7q36, with an autosomal dominant mode of inheritance. The HLXB9 gene is involved in motoneurons and caudal development of the embryo. However, genetic heterogeneity is suspected, since patients without HLXB9 mutation harbour subtle phenotypic variations. Presently, no other locus has been identified. The pre-sacral tumor develops in almost 80% of CS. When it is a teratoma (30% of cases), it may turn into malignancy in 1 to 4 % of cases, according to literature. As far as we know, no clinical, molecular or pathological marker is operational to predict tumoral evolution and give any prognosis. Major aim of this study is to find out any correlation between clinical signs, constitutional and somatic genetic anomalies of HLXB9 gene and other candidate genes, and/or pathological features and tumoral evolution in CS. Evaluation of the pre-sacral tumor evolution is based on local recurrence or distance metastasis after surgical removal. Annual serum alpha-foeto-protein level monitoring is also performed, as the unique marker of teratoma.This study specifically required annual clinical examination and lumbar-sacral MRI imaging, three blood samples at inclusion and an annual blood sample.This multicentric study will last for at least 6 years. Eighty patients will be included and follow up for at least 3 years. Finally, this study may help identify a group of at-risk patients for tumor development and malignant transformation if pre-sacral teratoma. It will also help define objective clinical, radiological, molecular, pathological and/or biological criteria for long lasting survey. In general, it may also contribute to support hypothesis of close relationships between genes involve in oncogenesis and those involve in embryological development.
Depression is the most common neuropsychiatric manifestation following stroke and current treatments are largely ineffective. Depression has both direct and indirect effects on response to rehabilitation, thus subjects with post-stroke depression (PSD) are routinely excluded from clinical trials and treatment options are extremely limited. The investigators propose to determine the impact of a novel, high-intensity resistance training program, Post-stroke Optimization of Walking using Explosive Resistance (POWER) training, on post-stroke depressive symptoms. Further, the investiators will determine if depression limits training-induced improvements in muscular and locomotor function. This project is based on the premise that depression negatively affects the potential for neuroplastic changes to occur in response to treatment such that rehabilitation may not produce the same adaptations that it does in non-depressed individuals. The investigators propose that effective treatment for PSD would result in a virtuous cycle where reducing depression enhances neuroplastic changes, thereby facilitating functional gains. That is, effectively treating depression will make the individual better able to recover from stroke. Furthermore, in addition to its beneficial effects on depression, POWER training is known to improve post-stroke walking, thus providing an attractive option for treating depression as well as an established vehicle to study the effects of PSD on response to rehabilitation. The experiments proposed as part of this project are designed to address critical questions related to 1) the effects of POWER training on depressive symptoms; 2) the potential for PSD to limit improvements following training; and 3) the interaction between improvements in depression and increases in walking function. Successful completion of this project will provide a foundation for larger scale trials to determine dosing parameters as well as establish therapeutic effectiveness of POWER training on post-stroke depression as well as identify the mechanisms that may be responsible for the changes that occur in response to treatment.
Participants will participate in a 12-week full-body resistance and aerobic exercise program. It will include full body resistance exercises two days a week and aerobic exercise program three days a week. For aerobic exercise, participants will be asked to do brisk walking 3 days a week. Participants will be called regularly to monitor their participation in the aerobic exercise program. Resistance exercises sessions will be supervised by a physical therapist. Each resistance training session will include five minutes of warm-up, forty minutes of resistance training and five minutes of cool-down. Resistance exercises will consist of weight-bearing exercises performed with the participant's own body weight. Participants in the exercise group will complete the questionnaires at baseline and after 12 weeks at the end of the intervention.
The invention discloses a shuttle expression vector p BES of bifidobacterium-colon bacillus and a bifidobacterium-ETECCFA/I recombinant vector constructed by the shuttle expression vector p BES of bifidobacterium-colon bacillus, as well as an oral live bacterin of the bifidobacterium-ETECCFA/I recombinant vector and purposes thereof. The p BES vector altered from the framework of the p GEX-5x-1 with the GenBank No. of U13856; the bifidobacterium-colon bacillus expression vector p BES is used for the expression of all foreign genes with the bifidobacterium as recipient bacterium. The bifidobacterium-colon bacillus shuttle expression vector p BES is used for constructing the bifidobacterium-ETECCFA/I recombinant vector; the ETEC CFA/I is the ETEC CFA/I of people. The oral live bacterin constructed by bifidobacterium-ETECCFA/I recombinant vector is used for preventing and curing the diarrhea diseases caused by ETEC. The invention can replace the traditional recipient bacterium of the CFA/I in the ETEC bacterin with the bifidobacterium through gene engineering measures; in this way, the safety problem of the vector system of constructing live bacterin is solved and micro-ecological effect of the bifidobacterium constraining the intestine pathogenic fungus.
Our laboratory is investigating the genetic basis of the vascular disease, in-stent restenosis. We hypothesize that patients with in-stent restenosis have abnormal expression of cell cycle regulatory and inflammatory genes that lead to accelerated development of vascular lesions following angioplasty, and that there is a genetic component underlying individual differences to vascular injury. We are conducting an investigation of human subjects with in-stent restenosis, entitled the CardioGene Study. The objective of the CardioGene study is to identify the genetic profile of patients at risk for in-stent restenosis. The CardioGene study completed enrollment of 465 patients in December 2004. Analysis of blood gene expression profiles, proteomic and genotyping data is currently ongoing. All analyses are conducted using peripheral blood. Concurrent analysis of restenosis tissue samples would be valuable in defining the molecular genetics of the disease.

In this complementary study of endartectomy tissues, we will collect diseased restenosis tissues removed from patients as part of their routine clinical care. We will also collect blood at the time of tissue harvesting for genomic analysis, in addition to clinical data. Genomic data will be compared to the CardioGene study findings, for the purposes of validation as well as more detailed understanding of the biology of restenosis, by investigation the molecular mechanisms of restenosis in the tissue samples.
The intelligent bone mineral density detection system based on the technology of the Internet of things is divided into a sensing layer, a communication layer and an application layer. The sensing layer is mainly formed by a sensor skeleton or an RFID (radio frequency identification) tag arranged on a monitored object, and the monitored object is sensed. The sensing skeleton is provided with a communication device which can communicate with the network layer and transmit a monitoring instruction or information attached to the skeleton. The core of the communication layer of the Internet of things is nodes arranged on a monitoring skeleton to form a multi-hop type self-organizing network. The application layer is arranged in the data center, and information collected by the perception layer is sorted and analyzed, so that human-computer interaction is realized, and detection personnel can inquire the information. The algorithm analyzes the sensed data to determine the current health condition of the bone, and if maintenance is required, a maintenance plan can be made for the inspector.
PROBLEM TO BE SOLVED: To obtain a preparation for external use for skin having both excellent tyrosinase and elastase inhibitory effect, thus effective for preventing skin whitening and aging. SOLUTION: This preparation contains 0.0005-20 (pref. 0.001-10)wt.%, on a dry basis, of an extract from a plant belonging to Theaceae Schima (e.g. Bunga cangkok, scientific name: Schima wallichii (DC) Korth) which grows esp. in the arid grassland and pastureland in Indonesia. The extracts can be obtained by immersing the leaves, stems, flowers, barks, seeds, fruits, whole grass, etc., of the plant in an extraction solvent (e.g. methanol) or refluxing them in the presence of the solvent under heating followed by filtration and then concentration. The preparation is obtained in the form of ointment, cream, milky lotion, lotion, pack, bathing agent, etc.  The preparation is excellent in color fading ability for pigmentation after suntan, spots, freckles, chloasma, etc., and in ability for skin whitening, and is effective for retaining fresh skin through preventing skin aging by recovering and maintaining skin firmness and elasticity.
Devices used to absorb bodily fluids include, but are not limited to, diapers, incontinence devices, feminine hygiene products, or wound dressings, for example. Certain embodiments of these devices are produced from a top sheet, an absorbent core, and back sheet. Embodiments of the top sheet have a nonwoven polymeric sheet having both water insoluble and water soluble urease inhibiting compounds. The water insoluble and water soluble urease inhibiting compounds may be copper compounds. For example, the nonwoven polymeric top sheet have polymeric fibers and the polymeric fibers include a plurality of first particles of water insoluble copper compounds that release at least one of Cu+ ions and Cu++ ions upon contact with a body fluid embedded in the polymeric fibers and water soluble copper compounds on the surface of the polymeric fibers. The devices also include water insoluble urease inhibiting compounds within the absorbent core.
Method for processing algae to algae extract, esp. for the food, pharmaceutical, and biochemicals inds., in which the ripe algae cells (pref. from algae culture) are pressed to remove adhering liquid; then heated for a sufficient length of time to release the cell contents from the cell wall; the undesired cell component are removed from the prodt. and the remaining cell components thickened to a pasty mass. Algae extracts are used for human and animal foodstuffs; as nutrient media for microorganisms and as sources of pharmaceuticals, enzymes etc. Sepd. cell-wall fragments are useful as cattle fodder. Removal of cell-wall fragments give a prodt. of improved digestibility, colour, odour and taste. Process gives higher yields/unit time than existing processes are obtd.
Trospium chloride extended-release capsules were evaluated for the treatment of patients with overactive bladder who had symptoms of urinary frequency, urgency and urge urinary incontinence in two 12-week, randomized, double-blind, placebo-controlled studies. For both studies, entry criteria required the presence of urge incontinence (predominance of urge), at least one incontinence episode per day, and 10 or more micturitions (voids) per day (assessed by 3-day urinary diary). Medical history and data from the baseline urinary diary confirmed the diagnosis. Approximately 88% of the patients enrolled completed the 12-week studies. The mean age was 60 years, and the majority of patients were female (84%) and Caucasian (86%).

The co-primary endpoints in the trials were the mean change from baseline to Week 12 in number of voids/24 hours (reductions in urinary frequency) and the mean change from baseline to Week 12 in number of incontinence episodes/24 hours. Secondary endpoints included mean change from baseline to Week 12 in volume per void.

Study 1 included 592 patients in both trospium chloride extended-release capsules 60 mg and placebo groups. As illustrated in Table 4 and Figures 2 and 3, trospium chloride extended-release capsules demonstrated statistically significantly (p<0.01) greater reductions in the urinary frequency and incontinence episodes, and increases in void volume when compared to placebo starting at Week 1 and maintained through Weeks 4 and 12.

Study 2 included 543 patients in both trospium chloride extended-release capsules 60 mg and placebo groups and was identical in design to Study 1. As illustrated in Table 5 and Figures 4 and 5, trospium chloride extended-release capsules demonstrated statistically significantly (p<0.01) greater reductions in urinary frequency and incontinence episodes, and increases in void volume when compared to placebo at Weeks 4 and 12. However, at Week 1, statistically significant reductions were seen in urinary incontinence episodes and volume void only.
The invention discloses an antibacterial peptide cecropin A mutant and a coding gene, a preparation method and application thereof, wherein the amino acid sequence of the mutant is shown as SEQ ID No: 3, respectively. The nucleotide sequence of the gene for coding the mutant is shown as SEQ ID No: 4, respectively. According to the gene sequence of the antibacterial peptide mutant PEW300 at the design position, the molecular cloning is carried out, the gene is cloned into a recombinant expression vector, and the high-efficiency expression of the mutant PEW300 is realized through the fusion expression with the self-aggregation short peptide ELK 16. And then carrying out 9 types of indicator bacteria bacteriostasis tests on the obtained mutant peptide PEW300, wherein the results show that the bacteriostasis performance of the antibacterial peptide PEW300 is greatly improved. And has strong pH and thermal stability. Hemolysis does not occur even when antibacterial peptide PEW300 is added at a high concentration.
Sepsis is a life-threatening condition with a rising disease burden worldwide. It is a multifactorial disease and is defined as a dysregulated host response to infection. Neutrophils have been shown to be involved in the pathogenesis of sepsis by exacerbating inflammation. However, the exact effector mechanism of action still remains a mystery. Changes in the glycosylation pattern of the immunoglobulin G (IgG) Fc region are described for several diseases including meningococcal sepsis. In this study, we investigated the possible contribution of neutrophils and neutrophil implication, potentially related to degranulation or neutrophil extracellular trap (NET) formation in changing the IgG Fc N-glycosylation pattern in a murine sepsis model. We have measured the serum level of cytokines/chemokines and immunoglobulins, the serum activity of neutrophil elastase (NE), and analyzed the IgG Fc glycosylation pattern by Liquid Chromatography-Electrospray Ionization-Mass Spectrometry (LC-ESI-MS) and Lectin enzyme-linked immunosorbent assay (ELISA). We observed an increased activity of NE- and neutrophil-associated cytokines such as keratinocyte chemoattractant (KC) with the development of sepsis. Regarding the IgG Fc N-glycosylation, we observed an increase in fucosylation and α1,3-galactosylation and a decrease for sialyation. Interestingly, these changes were not uniform for all IgG subclasses. After depletion of neutrophils, we saw a change in the exposure of fucose and α2,6-linked sialic acid during the time course of our experimental sepsis model. In conclusion, neutrophils can influence changes in the IgG glycosylation pattern in experimental sepsis.
Participants apply the 5% benzoyl peroxide gel every evening and the moisturizing cream every morning for 3 months. Then they are divided into 2 groups: one applies the anti-acne face cream every morning for 3 months and the other one the moisturizing cream every morning for 3 months.